泊沙康唑片剂亚治疗浓度的危险因素
本研究纳入157例接受泊沙康唑片剂预防侵袭性真菌感染的血液恶性肿瘤诱导治疗及异基因干细胞移植后GVHD患者,评估亚治疗谷浓度(<700 ng/mL)的危险因素。28例(18%)出现亚治疗浓度,腹泻、使用质子泵抑制剂及体重>90 kg与亚治疗浓度显著相关。提示片剂虽浓度更稳定,特定人群仍需治疗药物监测。
要点
- 18%患者泊沙康唑片剂谷浓度<700 ng/mL。
- 腹泻、质子泵抑制剂、体重>90 kg为亚治疗浓度危险因素。
- 高危患者仍需治疗药物监测以识别亚治疗浓度。
核心结论
- 泊沙康唑片剂治疗浓度较混悬液更稳定,但部分患者仍出现亚治疗谷浓度,特定人群需TDM。
研究设计与样本
- 回顾性分析2013年2月1日至2015年3月31日157例接受泊沙康唑片剂预防的血液恶性肿瘤诱导治疗及异基因干细胞移植后GVHD患者。
主要发现
- 28例(18%)患者泊沙康唑谷浓度<700 ng/mL。
- 腹泻患者中亚治疗浓度者24例(83%),P<0.001。
- 使用质子泵抑制剂者中亚治疗浓度者27例(93%),P=0.016。
- 体重>90 kg者中亚治疗浓度者14例(48%),P=0.047。
关键数值与推荐
- 亚治疗谷浓度定义为<700 ng/mL。
临床怎么用
- 对伴有腹泻、使用质子泵抑制剂或体重>90 kg的泊沙康唑片剂预防患者,应考虑治疗药物监测以识别亚治疗浓度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Posaconazole is the prophylactic antifungal of choice for patients with haematological malignancies at high risk of invasive fungal infections (IFIs). Studies have demonstrated that subtherapeutic concentrations of posaconazole are associated with breakthrough fungal infections and specific risk factors for subtherapeutic troughs associated with the suspension formulation have been identified. However, these risk factors have not been evaluated in a large patient population with the recently approved tablet formulation. OBJECTIVES: To determine the risk factors for subtherapeutic posaconazole troughs associated with the tablet formulation in patients receiving posaconazole as IFI prophylaxis. PATIENTS AND METHODS: From 1 February 2013 to 31 March 2015 all posaconazole serum trough concentrations were evaluated. A total of 157 patients receiving posaconazole tablet for prophylaxis during induction therapy for haematological malignancies and allogeneic stem cell transplant recipients with graft-versus-host disease were included for analysis. RESULTS: Overall, 28 patients (18%) had subtherapeutic troughs (<700 ng/mL). Patients were more likely to have subtherapeutic troughs if they had diarrhoea (n = 24; 83%) (P < 0.001), were receiving a proton pump inhibitor (n = 27; 93%) (P = 0.016) and weighed >90 kg (n = 14; 48%) (P = 0.047). CONCLUSIONS: While the posaconazole tablet has provided more consistent therapeutic concentrations when compared with the suspension there may still be a role for therapeutic drug monitoring (TDM). These results may guide us to a specific population in which TDM is necessary to identify subtherapeutic troughs.
引用
- Tang LA, Marini BL, Benitez L, et al. Risk factors for subtherapeutic levels of posaconazole tablet. J Antimicrob Chemother. 2017. PMID: 29091205. doi:10.1093/jac/dkx228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。